GeneType and Stayhealthy Announce Landmark Distribution Agre
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Genetic Technologies Limited has announced a distribution agreement with Stayhealthy for a Multi-Risk Test. This partnership aims to enhance the availability of the test through Stayhealthy's online pharmacy channel in North America. The collaboration is expected to empower individuals to manage their health more effectively by providing insights into health risks. Both companies expressed excitement about the partnership and its potential impact on health management.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Genetic Technologies Limited on 6ix
Earlier from Genetic Technologies
- GTG Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer
- Launch of test for 100% risk of breast and ovarian cancer
- GTG and Wellworks for You sign B2B sales and marketing deal
- Prospectus Supplement
- GTG announces US$2 Million Registered Direct Offering
Later from Genetic Technologies
- GTG Expands Operational Capacity in North America
- Genetic Technologies Expands Operational Capacity in North America
- GeneType identifies 79.5% at risk of serious disease
- GeneType to Enter Canadian and New Zealand Markets
- Genetic Technologies Announces Appointment of Chief Financial Officer & Company Secretary
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies